Caribou Biosciences, Inc.
No SEC Form 4 filings for $CRBU in the last 30 days.
See all $CRBU insider activity →Caribou Biosciences' average stock price target increased from $10 to $11 by 5 analysts, with a range of $1 to $32. This implies an 869% upside from the Oct. 6 closing price. The consensus rating remains 'Buy', with 3 Buys and 2 Holds.
Caribou Biosciences is halting its CRISPR-based CAR-T cancer therapy research and laying off staff due to funding challenges. The company will explore strategic alternatives, including mergers or acquisitions. Its shares have significantly declined since their 2021 peak. According to the CEO, the decision is not due to a lack of belief in the therapies' potential.
Caribou Biosciences, a biotech developing off-the-shelf CAR-T cell therapies, will discontinue its pipeline and lay off employees, citing shifting investor interest towards in vivo approaches. The company is exploring exit strategies, including mergers or acquisitions. Caribou's board attributes the decision to the current financing environment for allogeneic CAR-T therapies. The company had 97 employees as of February 2026, with substantial layoffs planned.
Over the past 7 days, AlphAI's AI scored 23 news stories mentioning CRBU (Caribou Biosciences, Inc.). Coverage has skewed bearish: 1 bullish, 1 neutral, and 21 bearish.
Recent CRBU coverage spans corporate actions, financial news and earnings.
Analyst price‑target increase suggests a bullish outlook.
The news signals severe funding challenges and program termination, likely triggering a sell‑off.
The pipeline wind‑down removes future revenue potential and signals financial distress, likely driving the stock lower.
Strategic alternatives signal potential sale or restructuring, pressuring the stock.
The downgrade and steep price‑target cut signal reduced growth expectations.
AlphAI scores every news story that mentions CRBU with an AI model for sentiment and relevance, and aggregates insider trades from Caribou Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Caribou Biosciences' average stock price target increased from $10 to $11 by 5 analysts, with a range of $1 to $32. This implies an 869% upside from the Oct. 6 closing price. The consensus rating remains 'Buy', with 3 Buys and 2 Holds.
1 min readCaribou Biosciences is halting its CRISPR-based CAR-T cancer therapy research and laying off staff due to funding challenges. The company will explore strategic alternatives, including mergers or acquisitions. Its shares have significantly declined since their 2021 peak. According to the CEO, the decision is not due to a lack of belief in the therapies' potential.
2 min readCaribou Biosciences, a biotech developing off-the-shelf CAR-T cell therapies, will discontinue its pipeline and lay off employees, citing shifting investor interest towards in vivo approaches. The company is exploring exit strategies, including mergers or acquisitions. Caribou's board attributes the decision to the current financing environment for allogeneic CAR-T therapies. The company had 97 employees as of February 2026, with substantial layoffs planned.
2 min readU.S. stocks fell Wednesday, with the Dow Jones dropping 350 points. Constellation Brands (STZ) reported better-than-expected Q2 earnings, beating estimates with $3.74 EPS and $2.633B sales. The company also acquired SpikedAde. Meanwhile, Caribou Biosciences (CRBU) shares dropped 47% after announcing strategic alternatives exploration. Commodities and European/Asian markets also declined.
2 min readRBC Capital downgraded Caribou Biosciences to Sector Perform with a $1 price target, an 11.9% downside from its Oct 6 close. The move follows Caribou's decision to discontinue its allogeneic CAR-T programs, citing financing challenges. The price target was reduced from $10, reflecting a more cautious outlook on the company's growth.
1 min readConstellation Brands (STZ) shares fell 5.1% in pre-market trading despite beating Q2 earnings and sales estimates, reporting $3.74 EPS and $2.633B revenue. The company also announced the acquisition of SpikedAde. Caribou Biosciences (CRBU) shares dropped 35.7% after exploring strategic alternatives and discontinuing two cell therapy programs.
2 min readCaribou Biosciences' CFO Sriram Ryali will leave upon the company's execution of a binding agreement for a strategic transaction. The termination is without cause and governed by Ryali's employment agreement. Details on the strategic alternative and replacement are not disclosed.
1 min readCaribou Biosciences (CRBU) is exploring strategic alternatives to maximize shareholder value and will discontinue development of its vispa-cel and CB-011 CAR-T cell therapy programs. The company had $113.8M in cash as of June 30, 2026, and plans workforce reductions. Wedbush Securities is advising on the process.
2 min readCaribou Biosciences, Inc. (CRBU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update -- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-ce
6 min readCaribou Biosciences, Inc. (CRBU) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. crbu-20260617 FALSE 0001619856 0001619856 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the
2 min read
